Roivant Posts $3.9B Cash, $209M Buyback, and Genevant's $950M Moderna Windfall
ROIV has more than doubled off its 52-week low of $10.9.
Summary
Roivant's Q1 update packs several material positives. Cash stands at $3.9 billion, boosted by a $950 million initial payment from the Moderna patent settlement received in July. The company bought back $208.7 million in shares during the quarter, signaling confidence. The brepocitinib launch in dermatomyositis is on track for end of September, and enrollment has started in a Phase 3 cutaneous sarcoidosis trial. Multiple topline readouts are due in H2 2026 across brepocitinib, IMVT-1402, and mosliciguat. This follows a transformative fiscal 2026 and sets up a catalyst-heavy second half. The cash runway extends to profitability, reducing financing risk.
At the time of this announcement, ROIV was trading at $35.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25B. The 52-week trading range was $10.90 to $37.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.